Stay updated on Ertugliflozin in Hypertension & T2D Sympathetic Activity Clinical Trial
Sign up to get notified when there's something new on the Ertugliflozin in Hypertension & T2D Sympathetic Activity Clinical Trial page.

Latest updates to the Ertugliflozin in Hypertension & T2D Sympathetic Activity Clinical Trial page
- Check7 days agoChange DetectedAdded a new Locations section with California as a site and updated the revision to v3.3.3. Removed the prior California Locations entry and the HHS Vulnerability Disclosure section, replacing the previous revision (v3.3.2) with v3.3.3.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision metadata was updated (Revision: v3.3.2 added; Revision: v3.2.0 removed). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedDeleted the generic government funding status notice from the page, removing guidance about potential delays and current operating status.SummaryDifference0.4%

- Check57 days agoChange DetectedNo additions or deletions detected; the page content remains unchanged.SummaryDifference0.4%

- Check85 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference2%

- Check92 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

Stay in the know with updates to Ertugliflozin in Hypertension & T2D Sympathetic Activity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ertugliflozin in Hypertension & T2D Sympathetic Activity Clinical Trial page.